Results 161 to 170 of about 17,878 (217)
Some of the next articles are maybe not open access.
Invasive Haemophilus influenzae Infections After 3 Decades of Hib Protein Conjugate Vaccine Use. [PDF]
Clinical Microbiology Reviews, 2021 Haemophilus influenzae serotype b (Hib) was previously the most common cause of bacterial meningitis and an important etiologic agent of pneumonia in children aged
Mary Slack, Keith Grimwood
exaly +2 more sources
Supporting New Vaccine Introduction Decisions: Lessons Learned From the Hib Initiative Experience
Vaccine, 2010 The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries.
A Chandran, M Santosham, E K Mulholland
exaly +2 more sources
Biological activity of Hib conjugates
Vaccine, 1991Haemophilus influenzae type b (Hib) conjugate vaccines dramatically improve the immunogenicity against the capsular polysaccharide (PRP) of Hib. A new Hib conjugate, PedvaxHIB, is shown to be immunogenic in infant rhesus monkeys. The monkey model appears to correlate well with the immunogenicity of PedvaxHIB in human clinical studies.
P P, Vella, J M, Staub, R W, Ellis
openaire +2 more sources
Predictable success of Hib vaccine
Nursing Standard, 1993It is of course wonderful news that the introduction of the Hib immunisation programme has cut the number of Hib meningitis cases by 70 per cent and that almost three-quarters of parents have responded to the campaign promoting the vaccine (News, 12 May).
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2008
Haemophilus influenzae type b (Hib) is the most common cause of bacterial meningitis among children. Hib conjugate vaccines, capsule polysaccharide (polyribosylribitol phosphate: PRP) conjugated with carrier protein, are very effective and safe. Hib vaccine conjugated with tetanus toxoid (PRP-T: ActHIB) was licensed in 1992 in France.
openaire +1 more source
Haemophilus influenzae type b (Hib) is the most common cause of bacterial meningitis among children. Hib conjugate vaccines, capsule polysaccharide (polyribosylribitol phosphate: PRP) conjugated with carrier protein, are very effective and safe. Hib vaccine conjugated with tetanus toxoid (PRP-T: ActHIB) was licensed in 1992 in France.
openaire +1 more source